Published in J Clin Oncol on May 20, 2008
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol (2011) 3.46
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol (2011) 2.38
Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol (2011) 1.86
Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol (2009) 1.65
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res (2012) 1.52
CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst (2011) 1.47
Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev (2010) 1.34
Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer. EBioMedicine (2015) 1.24
Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol (2010) 1.20
A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat (2015) 1.12
Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers. J Cancer Epidemiol (2014) 1.11
Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype. Breast Cancer Res (2013) 1.05
Integrative proteomics and tissue microarray profiling indicate the association between overexpressed serum proteins and non-small cell lung cancer. PLoS One (2012) 1.01
Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat (2012) 0.99
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol (2012) 0.94
Genome-wide gene expression profiling of formalin-fixed paraffin-embedded breast cancer core biopsies using microarrays. J Histochem Cytochem (2011) 0.93
Adjuvant therapy of triple negative breast cancer. Breast Cancer Res Treat (2010) 0.92
Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. Curr Oncol (2011) 0.91
Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res (2009) 0.90
Multiplexed quantification of estrogen receptor and HER2/Neu in tissue and cell lysates by peptide immunoaffinity enrichment mass spectrometry. Proteomics (2012) 0.90
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res (2012) 0.89
Retracted Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. Cell Mol Life Sci (2014) 0.84
Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Mod Pathol (2015) 0.84
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance. Breast Cancer Res Treat (2016) 0.83
Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age. Adv Ther (2015) 0.83
Performance of Three-Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev (2015) 0.81
Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. J Zhejiang Univ Sci B (2010) 0.81
Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay. PLoS One (2016) 0.81
In situ Protein Detection for Companion Diagnostics. Front Oncol (2013) 0.80
Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification. Breast Cancer Res (2016) 0.80
Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study. Acta Oncol (2011) 0.79
Quantitative analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5. Appl Immunohistochem Mol Morphol (2013) 0.78
Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection. Virchows Arch (2013) 0.78
Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry. J Exp Clin Cancer Res (2010) 0.78
Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. Clin Cancer Res (2011) 0.78
Estrogen receptor degradation: a CUE for endocrine resistance? Breast Cancer Res (2011) 0.77
Cancer is heterogeneous. J Clin Oncol (2009) 0.77
Problems and solutions in the evaluation of hormone receptors in breast cancer. J Clin Oncol (2008) 0.77
Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer. ISRN Oncol (2011) 0.77
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women. Front Oncol (2016) 0.76
Study assessing the quality of quantification of estrogen receptor protein expression by immunohistochemistry and gene expression in breast cancer. Patholog Res Int (2014) 0.76
TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer. Clin Cancer Res (2016) 0.76
Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65. Breast Cancer Res (2017) 0.75
Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients. Int J Breast Cancer (2017) 0.75
Automated measurement of estrogen receptor in breast cancer: a comparison of fluorescent and chromogenic methods of measurement. Lab Invest (2016) 0.75
Is immunohistochemistry less sensitive than quantitative reverse transcriptase polymerase chain reaction for hormone receptor status determination in breast cancer? J Clin Oncol (2009) 0.75
The analytical validation of the Oncotype DX Recurrence Score assay. Ecancermedicalscience (2016) 0.75
Life history theory and breast cancer risk: methodological and theoretical challenges: Response to "Is estrogen receptor negative breast cancer risk associated with a fast life history strategy?". Evol Med Public Health (2016) 0.75
Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach. Breast Cancer Res Treat (2015) 0.75
Prognostic and predictive value of low estrogen receptor expression in breast cancer. Curr Oncol (2017) 0.75
Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya. Trop Med Health (2017) 0.75
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Estrogen carcinogenesis in breast cancer. N Engl J Med (2006) 8.17
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med (2008) 6.54
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol (2007) 6.11
Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol (2002) 6.09
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol (2004) 5.29
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med (2010) 5.17
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol (2011) 4.81
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol (2010) 4.75
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol (2006) 4.61
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol (2006) 4.55
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med (2015) 4.53
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res (2006) 4.28
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol (2011) 4.12
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol (2003) 4.07
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol (2005) 4.03
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol (2008) 3.83
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol (2010) 3.79
Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2009) 3.70
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol (2008) 3.66
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol (2005) 3.63
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol (2008) 3.40
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst (2002) 3.34